Friday Pop Quiz 1/24/2025
In 2022 the FDA approved a medication for the treatment of the condition dipicted in the image. It inhibits the same enzymes as which of the following?
A. Ruxolitinib
B. Abrocitinib
C. Apremilast
D. Adalimumab
E. Tofacitinib
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
…
In 2022 the FDA approved a medication for the treatment of the condition dipicted in the image. It inhibits the same enzymes as which of the following?
A. Ruxolitinib
B. Abrocitinib
C. Apremilast
D. Adalimumab
E. Tofacitinib
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
… 
Alopecia areata (AA) is a common autoimmune disorder. Although its pathogenesis is not fully understood, AA involves CD8 T cell-mediated destruction of the hair follicle. Several treatment options exist; however, there is minimal evidence in the pediatric population. Currently, there are no curative treatments for AA. The literature suggests that Janus kinase (JAK) inhibitors may be an effective t … 
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … 
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Amit Pandya, staff dermatologist with Palo Alto Foundation Medical Group and adjunct professor in the department of dermatology at the University of Texas Southwestern Medical Center. Dr. Pandya says this is the most exciting time for him as a dermatologist with new vitiligo medications on the market an … 
At the 2023 ODAC Dermatology, Aesthetic & Surgical Conference, we were lucky to learn about the management of vitiligo from the renowned researcher and clinician, Dr. John Harris, Professor and Chair of Dermatology at the University of Massachusetts. When a new patient with vitiligo presents to my clinic, I always pull out my phone to consult Dr. Harris’ treatment protocol – I am sure I … 